{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260327252026/en/Lantern-Pharma-and-Starlight-Therapeutics-Announce-FDA-Clearance-of-IND-for-a-Planned-Phase-1-Pediatric-CNS-Cancer-Trial-of-STAR-001", "message": "News view counter 628765 successfully enlarged"}